19 May 2014
In this video, Professor Steve Conlan from Swansea University describes the development of a new technology for high-throughput epigenetics enabling fast and accurate results. Personalized medicine and companion diagnostics using epigenetic targets and biomarkers is a rapidly emerging area that shows great promise in the fight against cancer.
Reproductive Biology and Gynaecological Oncology, College of Medicine, Swansea University Medical School
Prof. Conlan leads Reproductive Biology and Gynecological Oncology research at Swansea University Medical School, investigating female health issues including endometrial (womb) and ovarian cancers, polycystic ovary syndrome (PCOS), endometriosis and in vitro fertilization (IVF). The team develop antibody-drug conjugates (ADC), nanoparticles drug delivery systems and exosomes for cancer treatment, biomarkers and nanosensors for disease diagnosis/monitoring, and investigate epigenetic/transcription disease mechanisms using Chromatrap™ technology co-developed by Porvair Ltd and Prof. Conlan’s group.